Targeting viruses using a modified sindbis glycoprotein
AssigneeUniversity of Pittsburgh
InventorsIra Bergman, Patricia Whitaker-Dowling
Life of this patent
Estimating the term…
Abstract
The present invention relates to viruses that are engineered to contain a surface ligand molecule which targets the virus to a cell of interest. In particular non-limiting embodiments, the cell of interest is desirably ablated and may be a cancer cell, an infected cell, a cell exhibiting a non-malignant proliferative disorder, or a cell of the immune system. Alternatively, the cell of interest is a target for gene therapy.
Claims7
An isolated recombinant vesicular stomatitis virus for producing a cytolytic effect in a target cell comprising (i) a modified Sindbis virus E2 protein replacing the G protein of vesicular stomatitis virus at the viral surface, where the modification decreases infectivity of the virus toward a cell that is not a target cell;
- and (ii) a single chain antibody that binds to an antigen present on a target cell.
Dependencies are inferred from the claim text.